
- 积分
- 116
- 威望
- 116
- 包包
- 291
|
各位大侠,紧急求助一篇文献,非常感谢!具体信息如下:
+ @* J3 C5 W. J4 O
9 C* u2 E9 A( j5 k. v: g1. Cell Transplant. 2014 Nov 5. [Epub ahead of print]* _7 x# \/ F/ A
" d/ s1 W) m. B4 QThe potential of human umbilical cord-derived mesenchymal stem cells as a novel! S- j7 U+ o# M* m$ K1 Y
cellular therapy for multiple sclerosis.- C- O" c7 Q* N) j9 r2 t
3 V7 y9 Y4 q* |5 ~Li JF, Zhang DJ, Geng T, Chen L, Huang H, Yin HL, Zhang YZ, Lou JY, Cao B, Wang: @% F% P2 b0 g/ h$ w+ T7 ~8 X* }6 b
YL.0 Q% H+ p D0 B6 A, Q& q4 Y
0 x! p I7 ~) E7 a7 }5 gMultiple sclerosis (MS) is a complex disease of neurological disability,4 l" L [% r( |4 m# `; c0 f7 J8 F$ u8 Z
affecting more than 300 out of every one million people in the world. The purpose" ?! i% L% p* f
of the study was to evaluate the therapeutic effects of human umbilical
# |: p( O9 B8 h' V5 rcord-derived mesenchymal stem cell (hUC-MSC) transplantation in MS patients.
& O6 G3 r; p' ?1 e9 eTwenty-three patients were enrolled in this study and 13 of them were given
2 [1 D6 {, S) `3 B+ O: |8 S. U4 |hUC-MSC therapy at the same time as anti-inflammatory treatment, whereas the
: x% F/ |0 O7 n- t5 Q& N- Mcontrol patients received the anti-inflammatory treatment only. Treatment
2 j# w$ q5 N# T6 U4 } K0 ]schedule included 1,000 mg/kg of methylprednisolone i.v. daily for 3 days and
2 R1 F3 T0 p' j% w, |6 lthen 500 mg/kg for 2 days, followed by oral prednisone 1mg/kg/day for 10 days.# A W, ^4 r* [
The dosage of prednisone was then reduced by 5mg every two weeks until reaching a
$ ] u& f; `: u( S5 P* q5mg/day maintenance dosage. Intravenous infusion of hUC-MSCs was applied three+ p& q1 x: j( n" t: X# @
times in a 6 week period for each patient. The overall symptoms of the hUC-MSC
8 D9 g2 @6 ^ f8 J; Ktreated patients improved compared to patients in the control group. Both the
2 C3 x. P* o9 U/ ]8 O" v0 a" u. oEDSS scores and relapse occurrence were significantly lower than those of the
4 Y& c1 t9 F% }; p! C$ fcontrol patients. Inflammatory cytokines were assessed, and the data demonstrated
! e) V( B9 ~4 M3 ~7 Q; ^a shift from Th1 to Th2 immunity in hUC-MSC treated patients. Our data. |* ?1 \9 |) Q* a4 X, e
demonstrated a high potential for hUC-MSC treatment of MS. This manuscript is
' Q) w* u f3 y) [6 xpublished as part of the International Association of Neurorestoratology (IANR)
. H1 H; e$ I2 aspecial issue of Cell Transplantation.% ]3 ]+ B2 m' j2 Y8 ?* D$ n C# I1 q
1 M' o/ V0 B! E% O' vPMID: 25385295 [PubMed - as supplied by publisher]
1 h3 k. L$ p( E' D6 S+ i: G$ q. F% g7 z5 \, ^. v
再次感谢!\(^o^)/~   |
|